Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura

Abstract

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by severe ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency, the presence of anti-ADAMTS13 autoantibodies and an open ADAMTS13 conformation with a cryptic epitope in the spacer domain exposed. A detailed knowledge of anti-ADAMTS13 autoantibodies will help identifying pathogenic antibodies and elucidating the cause of ADAMTS13 deficiency. We aimed at cloning anti-ADAMTS13 autoantibodies from iTTP patients to study their epitopes and inhibitory characteristics. We sorted anti-ADAMTS13 autoantibody expressing B cells from peripheral blood mononuclear cells of 13 iTTP patients to isolate anti-ADAMTS13 autoantibody sequences. Ninety-six B cell clones producing anti-ADAMTS13 autoantibodies were identified from which 30 immunoglobulin M (IgM) and 5 IgG sequences were obtained. For this study, we only cloned, expressed and purified the five IgG antibodies. In vitro characterization revealed that three of the five cloned IgG antibodies, TTP73–1, ELH2–1 and TR8C11, indeed recognize ADAMTS13. Epitope mapping showed that antibodies TTP73–1 and TR8C11 bind to the cysteine–spacer domains, while the antibody ELH2–1 recognizes the T2–T3 domains in ADAMTS13. None of the antibodies inhibited ADAMTS13 activity. Given the recent findings regarding the open ADAMTS13 conformation during acute iTTP, we studied if the cloned antibodies could recognize cryptic epitopes in ADAMTS13. Interestingly, all three antibodies recognize cryptic epitopes. In conclusion, we cloned three anti-ADAMTS13 autoantibodies from iTTP patients that recognize cryptic epitopes. Hence, these data nicely fit our recent finding that the conformation of ADAMTS13 is open during acute iTTP.

Keywords

thrombotic thrombocytopenic purpura - ADAMTS13 - anti-ADAMTS13 autoantibodies - cloning - cryptic epitopes

Authors' Contributions

E.R., G.V., O.J.H.M.V., F.P. and K.V. designed the experiments. E.R., K.K., O.J.H.M.V., L.D., I.P., N.V. and A.V. performed the experiments. I.M., C.V., M.A.A., L.G., M.S., D.D. and F.P. provided clinical information and PBMCs from iTTP patients. A.S.S. developed the antibody 1C4 and J.V. provided the antibodies II-1 and I-9. E.R., G.V., K.K., O.J.H.M.V., I.M., H.D. and S.F.D.M. and K.V. interpreted the data. E.R. and K.V. wrote the manuscript, which was critically reviewed by G.V., K.K., O.J.H.M.V., I.M., A.S.S., J.V., M.A.A., L.G., M.S., D.D., H.D., S.F.D.M. and F.P. All authors approved the final version of the manuscript. K.V. provided funding.

• References

• 1 Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276 (44) 41059-41063
• 2 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10) 4235-4244
• 3 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 (10) 4223-4234
• 4 Ostertag EM, Kacir S, Thiboutot M. , et al. ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro. Transfusion 2016; 56 (07) 1763-1774
• 5 Schaller M, Vogel M, Kentouche K, Lämmle B, Kremer Hovinga JA. The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. Blood 2014; 124 (23) 3469-3479
• 6 Pos W, Luken BM, Kremer Hovinga JA. , et al. VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7 (03) 421-428
• 7 Luken BM, Kaijen PHP, Turenhout EAM. , et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4 (11) 2355-2364
• 8 Foreman AL, Van de Water J, Gougeon ML, Gershwin ME. B cells in autoimmune diseases: insights from analyses of immunoglobulin variable (Ig V) gene usage. Autoimmun Rev 2007; 6 (06) 387-401
• 9 Siegel DL. Translational applications of antibody phage display. Immunol Res 2008; 42 (1-3): 118-131
• 10 Schaller M, Studt JD, Voorberg J, Kremer Hovinga JA. Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response. Hamostaseologie 2013; 33 (02) 121-130
• 11 Klaus C, Plaimauer B, Studt JD. , et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103 (12) 4514-4519
• 12 Zheng XL, Wu HM, Shang D. , et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 2010; 95 (09) 1555-1562
• 13 Luken BM, Turenhout EA, Hulstein JJJ, Van Mourik JA, Fijnheer R, Voorberg J. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2005; 93 (02) 267-274
• 14 Pos W, Sorvillo N, Fijnheer R. , et al. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica 2011; 96 (11) 1670-1677
• 15 Luken BM, Turenhout EA, Kaijen PHP. , et al. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost 2006; 96 (03) 295-301
• 16 Pos W, Crawley JTB, Fijnheer R, Voorberg J, Lane DA, Luken BM. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood 2010; 115 (08) 1640-1649
• 17 Soejima K, Matsumoto M, Kokame K. , et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003; 102 (09) 3232-3237
• 18 Thomas MR, de Groot R, Scully MA, Crawley JTB. Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. EBioMedicine 2015; 2 (08) 942-952
• 19 Muia J, Zhu J, Gupta G. , et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A 2014; 111 (52) 18584-18589
• 20 South K, Luken BM, Crawley JTB. , et al. Conformational activation of ADAMTS13. Proc Natl Acad Sci U S A 2014; 111 (52) 18578-18583
• 21 Deforche L, Roose E, Vandenbulcke A. , et al. Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13. J Thromb Haemost 2015; 13 (11) 2063-2075
• 22 Roose E, Schelpe A-S, Joly BS. , et al. An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2018; 16 (02) 378-388
• 23 Dohmen SE, Mulder A, Verhagen OJHM, Eijsink C, Franke-van Dijk MEI, van der Schoot CE. Production of recombinant Ig molecules from antigen-selected single B cells and restricted usage of Ig-gene segments by anti-D antibodies. J Immunol Methods 2005; 298 (1-2): 9-20
• 24 Feys HB, Roodt J, Vandeputte N. , et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood 2010; 116 (12) 2005-2010
• 25 Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138 (04) 534-540
• 26 Feys HB, Vandeputte N, Palla R. , et al. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8 (09) 2053-2062
• 27 Feys HB, Anderson PJ, Vanhoorelbeke K, Majerus EM, Sadler JE. Multi-step binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost 2009; 7 (12) 2088-2095
• 28 Lotta LA, Valsecchi C, Pontiggia S. , et al. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. J Thromb Haemost 2014; 12 (03) 329-336
• 29 Mancini I, Ferrari B, Valsecchi C. , et al; Italian Group of TTP Investigators. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura. Eur J Intern Med 2017; 39: 79-83
• 30 Mulder A, Kardol MJ, Kamp J. , et al. Determination of the frequency of HLA antibody secreting B-lymphocytes in alloantigen sensitized individuals. Clin Exp Immunol 2001; 124 (01) 9-15
• 31 Della Valle L, Dohmen SE, Verhagen OJHM, Berkowska MA, Vidarsson G, Ellen van der Schoot C. The majority of human memory B cells recognizing RhD and tetanus resides in IgM+ B cells. J Immunol 2014; 193 (03) 1071-1079
• 32 Fath S, Bauer AP, Liss M. , et al. Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS One 2011; 6 (03) e17596
• 33 Raab D, Graf M, Notka F, Schödl T, Wagner R. The GeneOptimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization. Syst Synth Biol 2010; 4 (03) 215-225
• 34 Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol 2004; 22 (07) 346-353
• 35 Plotkin JB, Robins H, Levine AJ. Tissue-specific codon usage and the expression of human genes. Proc Natl Acad Sci U S A 2004; 101 (34) 12588-12591
• 36 Vink T, Oudshoorn-Dickmann M, Roza M, Reitsma JJ, de Jong RN. A simple, robust and highly efficient transient expression system for producing antibodies. Methods 2014; 65 (01) 5-10
• 37 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129 (01) 93-100
• 38 Rojas OL, Narváez CF, Greenberg HB, Angel J, Franco MA. Characterization of rotavirus specific B cells and their relation with serological memory. Virology 2008; 380 (02) 234-242
• 39 Ferrari S, Scheiflinger F, Rieger M. , et al; French Clinical and Biological Network on Adult Thrombotic Microangiopathies. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109 (07) 2815-2822
• 40 Rieger M, Mannucci PM, Kremer Hovinga JA. , et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106 (04) 1262-1267
• 41 Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005; 280 (23) 21773-21778
• 42 Dogan I, Bertocci B, Vilmont V. , et al. Multiple layers of B cell memory with different effector functions. Nat Immunol 2009; 10 (12) 1292-1299
• 43 Froehlich-Zahnd R, George JN, Vesely SK. , et al. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica 2012; 97 (02) 297-303
• 44 Underwood MI, Thomas MR, Scully MA, Crawley JTB. Autoantibodies binding to “open” and “closed” ADAMTS13 in patients with acquired immune thrombotic thrombocytopenic purpura. RPTH 2017; 1 (01) 255
• 45 Alwan F, Vendramin C, Vanhoorelbeke K. , et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood 2017; 130 (04) 466-471